These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 35385572)

  • 21. The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors.
    Moeckel C; Bakhl K; Georgakopoulos-Soares I; Zaravinos A
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.
    Zhang Z; Wu HX; Lin WH; Wang ZX; Yang LP; Zeng ZL; Luo HY
    BMC Med; 2021 Feb; 19(1):26. PubMed ID: 33526018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities.
    Wang X; Lamberti G; Di Federico A; Alessi J; Ferrara R; Sholl ML; Awad MM; Vokes N; Ricciuti B
    Ann Oncol; 2024 Jun; 35(6):508-522. PubMed ID: 38537779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.
    Cheng L; Wang Y; Qiu L; Chang Y; Lu H; Liu C; Zhang B; Zhou Y; Bai H; Xiong L; Zhong H; Nie W; Han B
    J Transl Med; 2022 May; 20(1):247. PubMed ID: 35642038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment.
    Li H; Li J; Zhang C; Zhang C; Wang H
    Cancer Med; 2020 Oct; 9(19):7151-7160. PubMed ID: 32810393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients' sex.
    Wang S; Zhang J; He Z; Wu K; Liu XS
    Int J Cancer; 2019 Nov; 145(10):2840-2849. PubMed ID: 30972745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry.
    Jacob A; Wu J; Kolesar J; Durbin E; Mathew A; Arnold S; Chauhan A
    Cancer Med; 2021 Mar; 10(6):2054-2062. PubMed ID: 33619913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness.
    Quintanilha JCF; Storandt MH; Graf RP; Li G; Keller R; Lin DI; Ross JS; Huang RSP; Schrock AB; Oxnard GR; Chakrabarti S; Mahipal A
    JCO Precis Oncol; 2023 Jul; 7():e2300092. PubMed ID: 37410975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer.
    Sena LA; Fountain J; Isaacsson Velho P; Lim SJ; Wang H; Nizialek E; Rathi N; Nussenzveig R; Maughan BL; Velez MG; Ashkar R; Larson AC; Pritchard CC; Adra N; Bryce AH; Agarwal N; Pardoll DM; Eshleman JR; Lotan TL; Antonarakis ES
    Oncologist; 2021 Feb; 26(2):e270-e278. PubMed ID: 33215787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival.
    Wood MA; Weeder BR; David JK; Nellore A; Thompson RF
    Genome Med; 2020 Mar; 12(1):33. PubMed ID: 32228719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
    McGrail DJ; Pilié PG; Rashid NU; Voorwerk L; Slagter M; Kok M; Jonasch E; Khasraw M; Heimberger AB; Lim B; Ueno NT; Litton JK; Ferrarotto R; Chang JT; Moulder SL; Lin SY
    Ann Oncol; 2021 May; 32(5):661-672. PubMed ID: 33736924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
    Kim H; Kwon HJ; Kim ES; Kwon S; Suh KJ; Kim SH; Kim YJ; Lee JS; Chung JH
    Cancer Res Treat; 2022 Apr; 54(2):424-433. PubMed ID: 34237208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hot or Not: Tumor Mutational Burden (TMB) as a Biomarker of Immunotherapy Response in Genitourinary Cancers.
    Halbert B; Einstein DJ
    Urology; 2021 Jan; 147():119-126. PubMed ID: 33137348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
    Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrating tumor mutational burden and transcriptome expression into prediction of immune checkpoint inhibitor response and prognosis of patients with colon cancer.
    Liang L; Jiang W; Zheng Y; Liu TS; Shen XZ; Chen YJ
    J Physiol Pharmacol; 2022 Apr; 73(2):. PubMed ID: 35988929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.
    Voutsadakis IA
    Curr Oncol; 2022 Feb; 29(3):1390-1407. PubMed ID: 35323317
    [No Abstract]   [Full Text] [Related]  

  • 39. The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?
    Vegivinti CTR; Gonzales Gomez C; Syed M; Ferrell M; Cheng S; Singhi A; Saeed A; Sahin IH
    Expert Opin Biol Ther; 2023; 23(7):595-601. PubMed ID: 37318031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing.
    Wang HY; Deng L; Li YQ; Zhang X; Long YK; Zhang X; Feng YF; He Y; Tang T; Yang XH; Wang F
    Cancer Res Treat; 2021 Oct; 53(4):973-982. PubMed ID: 33677848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.